Trial Review

The ANZCTR website will be unavailable from 1pm until 3pm (AEDT) on Wednesday the 30th of October for website maintenance. Please be sure to log out of the system in order to avoid any loss of data.

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this information for consumers
Trial registered on ANZCTR


Registration number
ACTRN12612001112853
Ethics application status
Approved
Date submitted
17/10/2012
Date registered
17/10/2012
Date last updated
2/07/2018
Type of registration
Retrospectively registered

Titles & IDs
Public title
Using transcranial direct current stimulation (tDCS) to improve working memory in schizophrenia and healthy controls: investigating the role of current strength
Scientific title
Using transcranial direct current stimulation (tDCS) to improve working memory in schizophrenia and healthy controls: investigating the role of current strength at three time points post stimulation.
Secondary ID [1] 281405 0
Nil
Universal Trial Number (UTN)
Trial acronym
Linked study record

Health condition
Health condition(s) or problem(s) studied:
Schizophrenia 287650 0
Condition category
Condition code
Mental Health 287983 287983 0 0
Schizophrenia

Intervention/exposure
Study type
Interventional
Description of intervention(s) / exposure
Anodal transcranial direct current stimulation (tDCS) at 1mA and 2mA intensity. This will be applied to the left dorsolateral prefrontal cortex for 20 minutes using a neuroConn GBH/Eldith DC Stimulator. tDCS will be delivered during three sessions (1mA tDCS, 2mA tDCS, and sham tDCS) that will be at least 48 hours apart
Intervention code [1] 285893 0
Treatment: Devices
Comparator / control treatment
Sham transcranial direct current stimulation (tDCS). This will involve placing the electrodes in the same position as for active tDCS, however stimulation will be ceased after 30 seconds (so as to generate the same initial sensation and ensure blinding is maintained).
Control group
Placebo

Outcomes
Primary outcome [1] 288195 0
A statistically significant improvement in performance on a working memory task (i.e. N-Back) following application of tDCS stimulation, both in patients with schizophrenia/ schizoaffective disorder and in healthy controls.
Timepoint [1] 288195 0
Performance will be assessed immediately following stimulation, 20 minutes and 40 minutes post stimulation.
Secondary outcome [1] 299590 0
Nil
Timepoint [1] 299590 0
Nil

Eligibility
Key inclusion criteria
This study will involve both patients with schizophrenia and healthy controls. As such inclusion and exclusion criteria are defined separately for these groups.

Participants with schizophrenia will be included if they:
- are voluntary and competent to consent
- have a diagnosis of Schizophrenia or Schizoaffective Disorder as confirmed by the Structure Clinical Interview for the Diagnostic and Statistical Manual (DSM) -IV (SCID-IV)

Healthy individuals will be included if they:
- have capacity to consent
- have no personal history of psychiatric illness (lifetime) - based on self report.
Minimum age
18 Years
Maximum age
65 Years
Sex
Both males and females
Can healthy volunteers participate?
No
Key exclusion criteria
Patients with schizophrenia will be excluded if they:
- have a a DSM-IV history of substance abuse or dependence in the last 6 months
- have a concomitant major and/or unstable medical or neurologic illness
- are currently taking carbamazepine
- are currently pregnant or lactating
- have metal anywhere in the head, except the mouth (this includes metallic objects such as screws and clips from surgical procedures)

Healthy participants will be excluded if they:
- have an unstable medical condition, neurological disorder or are currently pregnant or lactating
- have metal in the cranium, a pacemaker, cochlear implant medication pump or other electronic device

Study design
Purpose of the study
Treatment
Allocation to intervention
Randomised controlled trial
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
This is a double-blind study. Neither the participant nor the researcher conducting the sessions will know what type of stimulation the participant is receiving during each session. . The stimulation condition will be counterbalanced across participants. A spreadsheet containing the six digit stimulation codes for each session randomised across conditions and participants is prepared by the chief investigator prior to recruitment commencing. Following the screening process and once the participant is enrolled in the study randomization takes place. At this time the Chief Investigator, who will be unblinded, will from this spreadsheet provide a unique six digit code to be entered into the tDCS stimulator, which will determine the stimulation condition and settings, thus allowing the second researcher to remain blinded.
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
Masking / blinding
Blinded (masking used)
Who is / are masked / blinded?



Intervention assignment
Crossover
Other design features
Phase
Not Applicable
Type of endpoint/s
Safety/efficacy
Statistical methods / analysis

Recruitment
Recruitment status
Completed
Date of first participant enrolment
Anticipated
29/05/2010
Actual
31/05/2010
Date of last participant enrolment
Anticipated
Actual
1/02/2013
Date of last data collection
Anticipated
Actual
8/02/2013
Sample size
Target
40
Accrual to date
Final
36
Recruitment in Australia
Recruitment state(s)
VIC

Funding & Sponsors
Funding source category [1] 286166 0
University
Name [1] 286166 0
Monash University
Country [1] 286166 0
Australia
Primary sponsor type
Individual
Name
Dr Kate Hoy
Address
MAPrc,
Level 4, 607 St Kilda Road
Melbourne VIC 3004
Country
Australia
Secondary sponsor category [1] 284978 0
None
Name [1] 284978 0
Address [1] 284978 0
Country [1] 284978 0

Ethics approval
Ethics application status
Approved
Ethics committee name [1] 288227 0
Alfred Human Research Ethics Committee
Ethics committee address [1] 288227 0
Ethics committee country [1] 288227 0
Australia
Date submitted for ethics approval [1] 288227 0
Approval date [1] 288227 0
05/05/2010
Ethics approval number [1] 288227 0
89_10

Summary
Brief summary
Trial website
Trial related presentations / publications
Public notes

Contacts
Principal investigator
Name 34842 0
A/Prof Kate Hoy
Address 34842 0
MAPrc, Level 4 607 St Kilda Road
Melbourne, VIC 3004
Country 34842 0
Australia
Phone 34842 0
+ 61 3 90765034
Fax 34842 0
Email 34842 0
[email protected]
Contact person for public queries
Name 18089 0
Ms. Sara Arnold
Address 18089 0
MAPrc,
Level 4, 607 St Kilda Road
Melbourne VIC 3004
Country 18089 0
Australia
Phone 18089 0
+61 3 9076 6592
Fax 18089 0
Email 18089 0
[email protected]
Contact person for scientific queries
Name 9017 0
Dr Kate Hoy
Address 9017 0
MAPrc,
Level 4, 607 St Kilda Road
Melbourne VIC 3004
Country 9017 0
Australia
Phone 9017 0
+61 3 9076 5034
Fax 9017 0
Email 9017 0
[email protected]

No information has been provided regarding IPD availability


What supporting documents are/will be available?

No Supporting Document Provided



Results publications and other study-related documents

Documents added manually
No documents have been uploaded by study researchers.

Documents added automatically
No additional documents have been identified.